Emerging novel therapies for advanced prostate cancer

Therapeutic Advances in Urology

Volumn 4, Issue 1, 2012, Pages 3-12

  Osanto, Susanne ^a   Van Poppel, Hendrik ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

abiraterone; cabazitaxel; castration resistant prostate cancer; denosumab; MDV3100; sipuleucel T; zoledronic acid

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; AFLIBERCEPT; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CABAZITAXEL; CANCER VACCINE; CYTOCHROME P450 17; DENOSUMAB; DOCETAXEL; ESTRAMUSTINE; GALETERONE; GONADORELIN AGONIST; IPILIMUMAB; LENALIDOMIDE; MITOXANTRONE; ORTERONEL; PLACEBO; PREDNISONE; RADIOISOTOPE; RADIUM 223; RADIUM CHLORIDE RA 223; SIPULEUCEL T; STEROID; TASQUINIMOD; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID;

ADRENAL INSUFFICIENCY; ADVANCED CANCER; ADVANCED PROSTATE CANCER; ANDROGEN DEPRIVATION THERAPY; ASTHENIA; BONE; BONE COMPRESSION; BONE DISEASE; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CASTRATION RESISTANT PROSTATE CANCER; CATHETER INFECTION; CHILL; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; FRACTURE; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SIDE EFFECT; SPINAL CORD COMPRESSION; STEROIDOGENESIS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84856054939     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287211432777     Document Type: Article

References (22)

1. Berthold D.R. Pond G.R. de Wit R. Eisenberger M. Tannock I.F. (2008) Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 19: 1749–1753.
2. Dahut W.L. Gulley J.L. Arlen P.M. Liu Y. Fedenko K.M. Steinberg S.M. (2004) Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22: 2532–2539.
3. De Bono J.S. Oudard S. Ozguroglu M. Hansen S. Machiels J.P. Kocak I. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376: 1147–1154.
4. De Bono J.S. Logothetis C.J. Molina A. Fizazi K. North S. Chu L. COU-AA-301 Investigators (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995–2005.
5. Ferlay J. Shin H.R. Bray F. Forman D. Mathers C. Parkin D.M. (2010) GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: IARC. Available from: http://globocan.iarc.fr (accessed 28 November 2011).
6. Fizazi K. Carducci M. Smith M. Damião R. Brown J. Karsh L. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377: 813–822.
7. Gulley J.L. Arlen P.M. Madan R.A. Tsang K.Y. Pazdur M.P. Skarupa L. (2010) Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 59: 663–674.
8. Higano C.S. Schellhammer P.F. Small E.J. Burch P.A. Nemunaitis J. Yuh L. (2009). Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115: 3670–3679.
9. Jemal A. Bray F. Center M.M. Ferlay J. Ward E. Forman D. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.
10. Jemal A. Center M.M. DeSantis C. Ward E.M. (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893–1907.
11. Kantoff P.W. Higano C.S. Shore N.D. Berger E.R. Small E.J. Penson D.F. (2010a) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411–422.
12. Kantoff P.W. Schuetz T.J. Blumenstein B.A. Glode L.M. Bilhartz D.L. Wyand M. (2010b) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28: 1099–1105.
13. Kelly W.K. Halabi S Carducci M.A. George D.J. Mahoney J.F. Stadler W.M. Cancer and Leukemia Group B (2010) A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 28(18 Suppl.): LBA4511.
14. Nilsson S. Franzen L. Parker C. Tyrrell C. Blom R. Tennvall J. (2007) Bone targeted radium-223 for in symptomatic hormone-refractory prostate cancer: a randomized multicentre placebo controlled phase II study. Lancet Oncol 8: 587–594.
15. Ning Y.M. Gulley J.L. Arlen P.M. Woo S. Steinberg S.M. Wright J.J. (2010) Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28: 2070–2076.
16. Petrylak D.P. Tangen C.M. Hussain M.H. Lara P.N. Jr Jones J.A. Taplin M.E. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520.
17. Picus J. Halabi S. Kelly W.K. Vogelzang N.J. Whang Y.E. Kaplan E.B. Cancer and Leukemia Group B (2011) A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer 117: 526–533.
18. Saad F. Gleason D.M. Murray R. Tchekmedyian S. Venner P. Lacombe L. Zoledronic Acid Prostate Cancer Study Group (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone refractory prostate cancer. J Natl Cancer Inst 96: 879–882.
19. Smith M.R. Egerdie B. Hernández T. N. Feldman R. Tammela T.L. Said F. (2009). Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361: 745–755.
20. Scher H.I. Beer T.M. Higano C.S. Anand A. Taplin M.E. Efstathiou E. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375: 1437–1446.
21. Small E.J. Schellhammer P.F. Higano C.S. Redfern C.H. Nemunaitis J.J. Valone F.H. (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24: 3089–3094.
22. Tannock I.F de Wit R. Berry W.R. Horti J Pluzanska A. Chi K.N. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512.